	US 12,435,125 B2
	Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft- versus-host disease
Subramanian V. Iyer, Royal Palm Beach, FL (US); and Sunny Patel, Stirling, NJ (US)
Assigned to Prodigy Biotech, West Chester, PA (US)
Appl. No. 18/555,338
Filed by Prodigy Biotech, West Chester, PA (US)
PCT Filed Apr. 15, 2022, PCT No. PCT/US2022/024946 § 371(c)(1), (2) Date Oct. 13, 2023, PCT Pub. No. WO2022/221616, PCT Pub. Date Oct. 20, 2022.
Claims priority of provisional application 63/175,603, filed on Apr. 16, 2021.
Prior Publication US 2024/0199723 A1, Jun. 20, 2024
Int. Cl. C07K 16/02 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 1/16 (2006.01); C07K 16/12 (2006.01)

CPC C07K 16/02 (2013.01) [A61K 9/0053 (2013.01); A61P 1/16 (2018.01); C07K 16/1228 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/11 (2013.01)]

10 Claims

1. A hyperimmunized egg produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis that expresses cytolysin toxin, and isolated Enterococcus faecalis cytolysin toxin, wherein the level of antibodies to the Enterococcus faecalis cytolysin toxin in the hyperimmunized egg is increased relative to an egg from an animal that has not been hyperimmunized, and wherein the titer of antibodies to Enterococcus faecalis cytolysin toxin in the hyperimmunized egg is at least 8000.